Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Aerobid Non-CFC Asthma Inhaler Launch Expected In Fall, C0O Says

Executive Summary

Forest will launch its non-CFC version of the prescription asthma inhaler Aerobid (flunisolide) this fall, President and Chief Operating Officer Kenneth Goodman told analysts on a conference call Jan. 16.

You may also be interested in...



FDA Warns Two Contract Research Sites Over Protocol Violations

Comprehensive Clinical Research has made several personnel changes in response to an FDA inspection that resulted in a June 5 warning letter

FDA Warns Two Contract Research Sites Over Protocol Violations

Comprehensive Clinical Research has made several personnel changes in response to an FDA inspection that resulted in a June 5 warning letter

Forest Phase III For Constipation-Predominant IBS To Begin In Late 2001

Forest will start Phase III trials for dexgloxiglumide in constipation-predominant irritable bowel syndrome before year-end.

Related Content

UsernamePublicRestriction

Register

PS037213

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel